Abstract: Embodiments of the present disclosure provide for contrast agents, methods of making contrast agents, and methods of using contrast agents, and the like.

Abstract: Compositions and methods of making a culture medium from a polymeric material are described herein. The method can include (a) depolymerizing and/or dispersing the polymeric material to obtain a depolymerized and/or dispersed residue, and (b) combining the depolymerized and/or dispersed residue with one or more adjuvants to form a culture medium. In some embodiments, the polymeric material can be a plastic article, such as a waste carpet material. Culture media prepared from the compositions and methods are also described. The culture media are suitable for culturing microorganisms including bacterium, algae, and fungus. The microorganisms can be used to produce a bioproduct such as a biopolymer, an enzyme, or a cellular metabolite.

Abstract: Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.

Abstract: Disclosed herein is a strategy for the engineering of recombinant vaccines against major human and animal pathogens of the paramyxovirus family. Also disclosed are recombinant virus able to replicate without being pathogenic. Also disclosed is a method of immunizing a subject against infection with a that involves administering to the subject a recombinant vaccine disclosed herein.

Abstract: This disclosure relates to benzhydrol derivatives for managing conditions related to the Hypoxia Inducible Factor (HIF) pathway such as uses in treating cancer. In certain embodiment, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiment, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof.

Abstract: Disclosed herein are inhibitors of PU.1. The inhibitors are useful for treating disorders associated with abnormal PU.1 levels and function.

Abstract: The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs.

Abstract: Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37° C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

Abstract: This disclosure relates bis-amine compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula (I), salts, derivatives, and prodrugs thereof wherein, A is a bridging aryl or heterocyclyl and R1 and R2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.

Abstract: Disclosed herein are compounds, compositions, and methods for identifying substrates of E3 ubiquitin ligases. The proteins, vectors, compositions, and may be utilized in methods for orthogonal ubiquitin transfer (OUT) between variant components of the ubiquitin cascade such as a variant ubiquitin (UB), a variant ubiquitin activating enzyme (E1), a variant ubiquitin-conjugating enzyme (E2), and a variant ubiquitin ligase (E3), which may include a variant HECT type, U-box type, RBR type, and/or Ring type E3 ligase. The variant components of the ubiquitin cascade typically include one or more mutations relative to their wild-type counterparts, such as amino acid substitutions, such that the variant components interact specifically and orthogonally with each of their variant components and do not interact with the wild-type counterpart of their variant components.

Abstract: The present invention provides methods of forming hydrogen sulfide. The methods include contacting a precursor compound with an unmasking agent; wherein the precursor compound comprises a hydrogen sulfide releasing moiety and a masked nucleophile; and wherein the contacting is conducted under conditions sufficient for cyclization of the precursor compound via lactone or lactam formation; thereby releasing hydrogen sulfide from the precursor compound. Hydrogen sulfide precursor compounds according to Formula I are also described, as well as methods for treating diseases and conditions using hydrogen sulfide precursors.

Abstract: Described herein are technologies for concentrating rare-earth elements from a heavy fraction of grit in gangue produced in kaolin mining. In some examples, grit is separated as a non-clay fraction of gangue produced in a kaolin mining operation. The grit is separated into a heavy mineral grit sub-fraction and a light mineral grit sub-fraction. Rare-earth elements, particularly heavy rare-earth elements, are thereafter extracted from the heavy mineral grit sub-fraction using various extraction technologies.

Abstract: Disclosed are recombinant chimeric influenza virus vaccines and live attenuated influenza virus (LAIV) vaccines expressing foreign (RSV) neutralizing epitopes or conserved M2e epitopes that are capable of providing broader cross-protection against influenza virus and/or protecting against respiratory syncytial virus (RSV) without vaccine-enhanced RSV disease (ERD).

Abstract: The present invention is directed to compositions including the cytokines IL-18 and IL-22 or biologically active fragments or variants thereof. In some embodiments, the compositions further include a pharmaceutically acceptable carrier. The compositions can further include other interleukins such as IL-1?, and IL 1? can be used as a combination therapy with either IL-18 or IL-22 or biologically active fragments or variants thereof.

Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.

Abstract: The present invention provides methods for detecting and/or treating a subject having an aneurysm or at risk for developing an aneurysm. It has been discovered that a key metabolite of the kynurenine (Kyn) pathway, a major route for the metabolism of essential amino acid tryptophan (Trp) into nicotinamide adenine dinucleotide (NAD+), plays a critical role in the formation of aneurysms, for example abdominal aortic aneurysms. In particular, it has been discovered that 3-Hydroxyanthranilic acid (3-HAA), a product of kynureninase (KYNU), plays a causative role in the formation of aneurysms by, for example exerting pro-inflammatory effects on vascular smooth muscle cells. It has further been discovered that elevated levels of 3-HAA are indicative of the presence and/or progression of an aneurysm, and 3-HAA levels correlate with the size (aortic diameter) of the aneurysm.

Abstract: Described herein are compounds that can bind CaSR and/or a CaSR extracellular domain and formulations thereof. Also described herein are methods of inhibiting CaSR and/or treating a disease or disorder associated with a mutation in CaSR by administering a compound or formulation thereof described herein. Also described herein are assays that can be used to identify compounds that can bind an extracellular domain of CaSR.

Abstract: In one embodiment, a system and method for assisting a physician with a hospital discharge decision pertain to collecting patient data from a patient under consideration who is staying at a hospital, estimating a mathematical probability of the patient under consideration being readmitted to the hospital within a predetermined amount of time if the patient under consideration were discharged on that day, wherein the mathematical probability estimate is based upon the collected patient data and patient data collected from a population of former hospital patients who had previously been discharged and whose readmission status is known, and providing information to the physician that assists the physician in deciding whether or not to discharge the patient under consideration, the information being based upon the results of the mathematical probability estimate.

Abstract: Rhein analogues that exhibit anti-proliferative activity, particular against cancer cells, are described herein. In some embodiments, the compounds contain a flat or planar ring system. Such rings system by facilitate non-covalent binding of the compounds to the DNA complex, such as by intercalation. In some embodiment, the compounds contain a flat or planar ring system as described above and one or more substituents which are alkylating moieties, electrophilic groups or Michael acceptors or groups which contain one or more alkylating moieties, electrophilic groups and/or Michael acceptors. The compounds described herein can also contain one more functional groups to improve the solubility of the compounds.

Abstract: A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.